Medindia

X

ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.

Thursday, July 8, 2010 General News J E 4
Advertisement


CHICAGO, July 7 ICAP Ocean Tomo, the intellectual property brokerage division of ICAP plc (IAP.L), is offering for sale a patent portfolio related to the advanced drug formulation technology Captisol® owned by CyDex Pharmaceuticals Inc. The portfolio contains two US-issued patents and fifteen related foreign counterparts covering two important close-to-market, 505(b)(2), Captisol-enabled product opportunities: Captisol-enabled Fosphenytoin and Captisol-enabled Propofol.

(Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100614/CG20517LOGO)

The advanced drug technology of CyDex's Captisol® is based on a modified cyclodextrin molecule that enables the creation of new products by significantly improving the solubility, stability, bioavailability, safety, and dosing of active pharmaceutical ingredients. Captisol-enabled(TM) Fosphenytoin is the advanced formulation of Fosphenytoin which is approved in the US for the short term treatment of epilepsy. This formulation offers advantages over the traditional product as it lowers pH and enables storage of the product at room temperature for up to two years. Captisol-enabled(TM) Propofol is an improved formulation over Propofol, an injectable general anesthetic. This formulation enhances the stability, reliability, and effectiveness of Propofol while reducing the potential for pain and allergic response. Unlike existing formulations, Captisol-enabled(TM) Propofol is pharmaceutically stable and does not degrade with exposure to light, oxidation, or the presence of divalent or trivalent cations.

"Both of these Captisol-enabled opportunities are very close to market and should be considered valuable assets to pharmaceutical manufacturers, distributors, branded generic companies, or specialty pharma companies looking to enhance their product offering, including those companies focused on injectable product opportunities," said Dean Becker, ICAP Ocean Tomo CEO.

To learn more about the patents available for sale in this portfolio or how to sell or buy intellectual property please contact Cameron Gray, Senior Vice President, ICAP Ocean Tomo at 650-421-3089 or at cameron.gray@us.icap.com.

About ICAP Ocean Tomo LLC

ICAP Ocean Tomo is the intellectual property brokerage division of ICAP.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP is also the source of global market information and research for professionals in the international financial markets. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.

SOURCE ICAP Ocean Tomo
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cambridge Health Alliance Nurses File Unfair Labor...
S
Cargill Helps Food Manufacturers Incorporate Oligg...